MxT = Microfluidics x Therapy
Microfluidic Gene Editing for Cell Therapy Starts Right Here
We transform cancer immunotherapy, cellular engineering
and genome editing with our patented non-viral genome editing technology, Hydroporator™
Technology
Hydroporator™: Next-Generation Microfluidic cellular engineering platform accelerating the discovery, development and manufacturing of novel cell therapies
Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high delivery efficiency, easy operation, low cost, high scalability, minimal cell perturbation (i.e., preserved cell function and viability), and cell type/cargo insensitive delivery. Hydroporator™ is free from the challenges from viral transduction, lipofection and electroporation, establishing a new avenue to accelerate cancer immunotherapy, cellular engineering and genome editing.
Fundamental advantages
Unlimited in cargo type including large sizes
Maintains viability
Highly efficient
Scalable from R&D into clinic
Effective for variety of cells
Preserved Cell Viability & Function
High Speed & Throughput Capability
Simple and Scalable
Strong Clinical Applicability
| Technologies | Efficiency | Nanoparticle delivery | Primary cell applicability | Viability | Scalability (per run) |
Cost |
|---|---|---|---|---|---|---|
| Electroporation |  (depends on cell and cargo type) |
(high Stokes drag) |
(low viability) |
(depends on cell type) |
High (104-106 cells per run) |
$10K to 100K |
| Microinjection |  (theoretically high) |
|
|
(depends on cell type) |
Low (100 cells per hour) |
$10K (injector only) |
| Viral transduction | (limited in DNA size) |
 (packaging failure) |
|
(mutagenesis concern) |
Low to High (depends on viral amount) |
High (preparation) |
| Lipofection | (depends on cell and cargo type) |
(packaging failure) |
(low efficiency for suspension cells) |
(depends on cell type) |
Low to High (depends on reagent amount) |
$1K/50 tests |
| Hydroporator™ | (>90% for human primary T cell) |
(> 300 nm) |
(immunocyte, stem cell....) |
(> 80%) |
High (106 cells per min per channel) |
~$1 (chip fabrication) |
Table reference: “Microfluidic and nanofluidic intracellular delivery”, Advanced Science (IF=16.806), 2004595 (2021)
Publications
Our Team
Aram Chung, Ph.D.
CEO & Founder
Yeonho Choi, Ph.D.
Executive Director
Soon-Tae Lee, M.D., Ph.D.
Scientific Advisor
Chin-Ha Chung, Ph.D.
Scientific Advisor
Gi-Beom Kim
Director of Engineering
Byeongju Joo
Senior Researcher
Hojong Lee
Assistant Researcher
Jiyeon Han
Administrative Staff
IR & News
'세포 내 물질 전달 플랫폼' 특허 출원 완료
*출원 내용
Application Number : 10-2021-0047258
Title of Invention…
한국산업기술진흥협회(KOITA)로부터 ‘연구개발전담부서’ 인증
과학기술정보통신부는 한국산업기술진흥협회를 통해 ‘기초연구진흥 및 기술개발지원에 관한 법률’에 따라 기업의 기술개발을 유도하고자…
(주)엠엑스티 바이오텍(MxT Biotech) 정아람 대표이사는 2022년 2월 5-9일 미국 보스턴에서 열린 SLAS( Society for…
[2022.01.19.] 관성을 기반으로 한 세포 내 전달 미세 유체 플랫폼, 특허 등록 완료
본…
Partners
We are grateful to be collaborating with great partners. With their generous support, we are moving towards achieving our mission. We welcome you to join our steps towards our mission.
Contact
Contact info
#907, Ttukseom-ro 17ga-gil 48, Seongdong-gu, Seoul, 04785, Republic of Korea
02-2157-4808 contact@mxtbiotech.com
02-2157-4808 contact@mxtbiotech.com
